The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and mainly be driven by an increase in approval of a ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

The approvals were based on positive results from EV-302, in which Padcev plus Keytruda resulted in statistically significant ...

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

What is a menopause health assessment? And how will it improve the health care women receive during this stage in their lives ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

A robotic device developed by University of Utah engineers allows eye surgeons to perform high-precision procedures on the retina, the fragile lining on the back of the eye that is less than a ...